strated clinical benefits with the simultaneous use of multiple RAAS inhibitors. [4] [5] [6] [7] The direct renin inhibitors (DRIs) represent another pharmacologically distinct method for RAAS blockade with the theoretical benefit of upstream RAAS inhibition at the point of pathway activation. Aliskiren, a first-in-class orally active DRI approved for the treatment of hypertension, has demonstrated a favorable hemodynamic and neurohormonal profile in patients with HF with potential to decrease blood pressure, increase renal blood flow, and reduce natriuretic peptides. [8] [9] [10] In the Aliskiren Observation of Heart Failure Treatment (ALOFT) study for patients with chronic HF (New York Heart Association [NYHA] class II-IV), aliskiren administered in addition to standard therapy significantly reduced brain natriuretic peptide (BNP) level and plasma renin activity compared with placebo. 10 Furthermore, aliskiren was associated with a significant reduction in urinary aldosterone excretion, supporting the hypothesis that a DRI strategy may reduce aldosterone escape.
Despite current evidence-based therapies, patients with hospitalization for HF (HHF) face postdischarge mortality and rehospitalization rates as high as 15% and 30%, respectively, within 60 to 90 days. [11] [12] [13] Incomplete suppression of the RAAS may contribute to the exceptionally high postdischarge event rate.
14 Therefore, we hypothesized that the addition of a DRI may improve long-term outcomes. The Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) study was designed to evaluate the effect of in-hospital initiation of aliskiren, in addition to standard therapy, on postdischarge mortality and HF rehospitalization within 6 months in HHF patients with reduced LVEF.
METHODS
The design of the study has been described previously. 15 ASTRONAUT was a prospective, multicenter, randomized, double-blind, placebo-controlled trial that assessed HHF patients after hemodynamic stabilization. Patients were considered eligible if they had a history of chronic HF defined as requiring standard therapy for 30 days or longer prior to the index hospitalization, were 18 years of age or older, had LVEF 40% or less, had elevated levels of natriuretic peptides (BNP Ն400 pg/mL or Nterminal pro-BNP [NT-proBNP] Ն1600 pg/mL) at admission, and had signs and symptoms of fluid overload that required hospitalization. Before randomization, patients were required to be hemodynamically stable, defined as systolic blood pressure 110 mm Hg or greater for at least 6 hours and no use of intravenous vasodilators (except nitrates) or intravenous inotropes from the time of hospital presentation to randomization.
Criteria for exclusion included myocardial infarction, cardiac surgery, or stroke within 3 months prior to enrollment; presence of ventricular assist devices or any type of mechanical support; history of a cardiac transplant or listed for transplant at time of enrollment; hemodynamically significant uncorrected primary cardiac valvular disease; right HF due to pulmonary disease; estimated glomerular filtration rate (eGFR) less than 40 mL/min/ 1.73 m 2 ; serum sodium level less than 130 mEq/L; serum potassium level greater than 5.0 mEq/L; and comorbid conditions with an expected survival of less than 3 years.
Institutional review board or ethics committee approval was obtained at each site. Potential participants were initially treated with standard therapy, at which time the diagnosis of worsening chronic HF and study eligibility were confirmed (visit 1). After providing written informed consent, hemodynamically stable patients were randomized in a 1:1 ratio to receive 150 mg of aliskiren or placebo daily, in addition to standard therapy, prior to the hospital discharge (visit 2). Standard HF therapy included but was not limited to diuretics, digoxin, ACE inhibitors, ARBs, ␤-blockers, and MRAs at the discretion of the treating physician. Patient data regarding baseline demographic characteristics, vital signs, other laboratory and diagnostic testing, and enrollment medications were recorded. Self-identified race (ie, white, black, Asian, Native American, Pacific Islander, other) and ethnicity (ie, Hispanic/Latino, Chinese, Indian, Japanese, mixed, other) data were also collected. Data regarding history of comorbid medical conditions were determined and reported by the study investigators.
One week after randomization (visit 3, week 1), patients were assessed for drug safety and tolerability compared with background standard therapy and continued to receive either aliskiren, 150 mg, or placebo. Two weeks after randomization (visit 4, week 2), the study medication was increased to 300 mg of aliskiren or placebo unless the patient could not tolerate the initial medication dose (such as development of low blood pressure, hyperkalemia, or worsening renal function). Patients returned 2 weeks after this dose change (visit 5, week 4) to ensure that the 300-mg dose was well tolerated. Additional study visits were scheduled for months 2, 3, 6, 9, and 12. Electrolyte levels (ie, serum potassium, serum sodium) and renal function (ie, serum creatinine, eGFR) were measured at every visit. Patients not tolerating the 300-mg study medication dose could be down-titrated to the 150-mg dose at the investigators' discretion at any time during the study.
The original study protocol allowed patients to continue receiving the study drug beyond 12 months, although secondary end points were evaluated at 12 months. However, in accordance with protocol amendment 2 (dated July 5, 2010) , maximum follow-up time was subsequently limited to 12 months for all patients. When the planned number of events was projected to be accrued, the study was continued until all patients reached a minimum follow-up time of 6 months (protocol amendment 3 dated November 3, 2011).
Study End Points
The primary end point was the first occurrence of cardiovascular (CV) death or rehospitalization for HF at 6 months (ie, 190 days) after randomization. The key secondary end point was the first occurrence of CV death or rehospitalization for HF within 12 months of randomization. Other secondary end points included first CV event (defined as CV death, HF hospitalization, nonfatal myocardial infarction, nonfatal stroke, and resuscitated sudden death) within 12 months; all-cause mortality within 6 and 12 months; changes from baseline in NT-proBNP level (at months 1, 6, and 12); and quality of life (activities of daily living, assessed by the Kansas City Cardiomyopathy Questionnaire at months 1, 6, and 12). All potential study end points were adjudicated by a blinded clinical event committee (Brigham and Women's Hospital, Harvard Medical School). An independent data monitoring committee was charged to monitor patient safety every 6 months during the trial.
Statistical Analysis
A total of 1782 participants (891 per treatment group) were planned for randomization to reach 381 patients with primary events (ie, CV death or HF rehospitalization within 6 months). This sample size was determined to have 80% power to reject the null hypothesis of equal hazard rates between aliskiren and placebo, assuming exponential survival curves, a 25% event rate in the placebo group at 6 months, a hazard ratio (HR) of 0.75 (25% reduction for superiority of aliskiren vs placebo), a common exponential dropout rate of 10%, and ␣ = .0495 (2-sided).
15, 16 The calculation of sample size was based on a maximum likelihood comparison of survival curves within 6 months. The 25% event rate was based on the published literature. 17 Given the high event rate in this patient population, the 25% reduction in HR for superiority of aliskiren was deemed to represent a clinically meaningful reduction in events.
A blinded evaluation was planned to assess the observed event rate of the primary end point and to reassess the sample size. All events (ie, number of events and time of event) for the primary end point were included in the interim analysis such that the results were available approximately 1.5 months prior to the completion of the projected recruitment. Because of the unexpected results of the Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints (ALTITUDE) 18 and a subsequent recruitment hold, a blinded sample size review of ASTRONAUT was performed as planned in the protocol and documented in a report from an independent statistician. After this sample size evaluation, it was concluded that the expected number of patients with the primary end point would be achieved with the 1639 patients already randomized. Hence, the study recruitment was stopped early because the required power was projected to have been reached.
The time-to-event data were assumed to follow a proportional hazard model. The null hypothesis was tested at the 2-sided significance level ␣ = .0495 using the Cox proportional hazard regression model with treat- ment and 7 prespecified covariates: log (base2) NT-proBNP (central laboratory measured at baseline), region, age, baseline systolic blood pressure, baseline LVEF, baseline serum creatinine level, and baseline serum sodium level (baseline refers to visit 2). A multiple imputation model was used to impute missing baseline covariates. An estimate of the HR and its associated 2-sided 95% confidence interval were provided by handling of ties with "exact" method from the inference of treatment effect. Kaplan-Meier tabulation was provided for each treatment group. Time-to-event data for secondary end points were analyzed using the same model described for the primary variable. Continuous variables are presented as means with standard deviations, whereas categorical variables are presented as counts and percentages of participants with available data.
All analyses were conducted according to a modified intent-to-treat principle where misrandomized patients were excluded from all efficacy analyses. All patients who received at least 1 dose of the study medication and who were not associated with site-specific Good Clinical Practice (GCP) violations were included in final analyses.
Exploratory analyses were performed for the primary end point and the selected secondary end points (CV death or HF rehospitalization at 12 months, all-cause mortality at 12 months) to assess the consistency of treatment effects across the following subgroups of interest: age with cutoff of 65 and 75 years, sex, race, region, baseline eGFR with 60 mL/min/1.73 m 2 cutoff, NYHA class I/II and III/IV, history of diabetes mellitus (DM), digoxin use, ␤-blocker use, MRA use, ACE inhibitor or ARB use, use of ACE inhibitor or ARB plus MRA, LVEF, presence of atrial fibrillation, systolic blood pressure, HF etiology, presence of an implantable cardioverter-defibrillator, baseline QRS, baseline NTproBNP level, baseline plasma renin activity, and baseline troponin I level.
Database management was performed by the sponsor according to a The follow-up period ended in July 2012. A total of 24 patients were excluded from the full analysis set due to either failure to ever receive study treatment or GCP violations at the study site. Therefore, the final cohort for efficacy analyses included 1615 patients (808 assigned to aliskiren, 807 assigned to placebo). Overall, 98.9% of patients completed the primary efficacy phase (day 190 or death). There were a total of 17 patients (1.1%) with unknown vital status at 6 months and 29 (1.8%) at 12 months or end of the study (FIGURE 1). Median follow-up was 11.3 months (interquartile range, 9.1-12.4 months). The mean age of the study cohort was 64.6 years; mean LVEF, 28%; and mean eGFR, 66.7 mL/min/1.73 m 2 . At admission and randomization, median NTproBNP levels were 4239 pg/mL and 2718 pg/mL, respectively. At randomization, patients were receiving diuretics (95.9%), ␤-blockers (82.5%), ACE inhibitors or ARBs (84.2%), and MRAs (57.0%).There were no major differences between the 2 treatment groups at the time of randomization (TABLE 1).
Primary End Point
The primary and selected secondary outcomes are summarized in TABLE 2. A total of 201 patients in the aliskiren group (24.9%) and 214 patients in the placebo group (26.5%) experienced the primary end point (HR, 0.92; 95% CI, 0.76-1.12; P=.41). The individual components of the primary end point contributed equally to the observed HR for the composite end point (HR, 0.92 and 0.90 for CV death and HF rehospitalization, respectively).
The placebo event rate assumed for the calculation of the original sample size (25% at 6 months) was consistent with the observed value in the placebo group (26.5%). Kaplan-Meier estimates for time to the primary composite end point are depicted in FIGURE 2.
Secondary End Points Within 6 and 12 Months
The key secondary end point of the composite of CV death or HF rehospitalization within 12 months did not differ between the treatment groups. Similarly, there was no statistically significant difference in first CV event (defined as CV death, HF hospitalization, nonfatal myocardial infarction, nonfatal stroke, and sudden death with resuscitation) within 12 months and all-cause death within 6 and 12 months. Although the time to first CV event did not reach statistical significance, events were numerically less frequent in the aliskiren group for the composite and the individual components. In this regard, the myocardial infarction component showed a statistically significant difference in favor of aliskiren (P=.009).
During the overall follow-up period (ranging from 0.1 to 31.2 months), the total hospitalization rates (ie, percentage of patients hospitalized for any reason) in the aliskiren and placebo groups were 48.1% and 49.1%, respectively. The HF hospitalization rates within 12 months were 26.2% in the aliskiren group and 27.8% in the placebo group. Slightly higher HF hospitalization rates occurred when examining the entire follow-up period (26.6% and 28.6% in the aliskiren and placebo treatment groups, respectively).
Aliskiren was associated with a statistically significant decrease in NTproBNP level compared with placebo at each time point tested (months 1, 6, and 12) (eTable 1, available at http: //www.jama.com). Mean (SD) changes in systolic blood pressure at 6 and 12 months were Ϫ1.46 (18.12) 
Subgroup Analysis
As shown in FIGURE 3 and the eFigure, for both the primary end point and CV death at 6 months there was no evidence for heterogeneity of treatment effects for any of the subgroups (all treatment ϫ subgroup interactions showed a PϾ.05).
For the secondary 12-month composite end point of CV death and HF rehospitalization, there was a statistically significant interaction with treatmentϫDM status at baseline (DM group: HR, 1.16; 95% CI, 0.91-1.47; non-DM group: HR, 0.80; 95% CI, 0.64-0.99; P = .03 for interaction). For allcause death by 12 months, there was a statistically significant interaction between treatment and DM status at baseline (DM group: HR, 1.64; 95% CI, 1.15-2.33; non-DM group: HR, 0.69; 95% CI, 0.50-0.94; P Ͻ.001 for interaction). Among patients with a history of DM, 24.1% of patients died during the double-blind treatment period in the aliskiren group compared with 17.4% patients in the placebo group. In contrast, the rates of death among patients without a history of DM were 15.3% and 20.0% in the aliskiren and placebo groups, respectively. In ASTRONAUT, 41.8% of patients with DM were receiving insulin therapy and 53.2% were receiving oral antihyperglycemic agents. No other significant interactions by treatment groups were seen with other subgroups for the 12-month end points.
Safety
Safety was evaluated in all patients included in the efficacy analysis plus 3 additional placebo patients (1 patient missing informed consent, 2 patients with associated GCP violations, for a total N=1618). Total numbers of adverse events (AEs), serious AEs (SAEs), discontinuations due to AEs, and abnormal laboratory values during the double-blind period are summarized in TABLE 3. There were similar proportions of patients with AEs leading to the discontinuation of the study treatment in both groups and a higher proportion of patients who discontinued the study drug for SAEs in the placebo group (9.8% vs 13.3%, respectively). Discontinuation of the study drug due to nonserious AEs was higher in the aliskiren group (11.8% vs 7.4%). The most frequently reported AEs are summarized in eTable 2.
Patients who received aliskiren were more likely to experience hyperkalemia, hypotension, and renal impairment. Hyperkalemia (Ͼ5.5 mmol/L and Ͻ6.0 mmol/L) and severe hyperkalemia (Ն6.0 mmol/L) were more frequent in the aliskiren group compared with the placebo group (14.3% vs 12.9% and 8.1% vs 5.1%, respectively) (eTable 3). Decrease in the eGFR levels to less than 30 mL/min/1.73 m 2 were also more frequent in the aliskiren group (10.9% vs 9.1%).
The incidences of AEs of interest (hyperkalemia, hypotension, and renal dysfunction) are summarized in Table 3 . Hyperkalemia-related AEs were more frequently reported in the aliskiren group compared with the placebo group (20.9% vs 17.5%). The percentage of patients who reported hypotensionrelated AEs was higher in the aliskiren group than in the placebo group (17.1% Median values for variables dichotomized at the median were ejection fraction, 29%; NT-proBNP, 2718 pg/mL; PRA, 3.0 ng/mL/h; SBP, 120 mm Hg.
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COMMENT
The ASTRONAUT trial was designed to evaluate the effect of in-hospital initiation of aliskiren after clinical stabilization, in addition to standard therapy, on postdischarge morbidity and mortality in HHF patients with reduced LVEF. Overall, aliskiren therapy had no significant effect on the primary composite end point of CV mortality or rehospitalization for HF at 6 months. Aliskiren treatment also had no effect on 6-month or 12-month clinical end points. However, the addition of aliskiren to standard therapy was associated with significantly larger decreases in N T -p r o B N P l e v e l s d u r i n g t h e 12-month follow-up. As expected, AEs of interest (hyperkalemia, hypotension, and renal impairment/renal failure) were more frequent in the aliskiren group compared with the placebo group, in line with the aliskiren mechanism of action. The RAAS represents a longestablished therapeutic target in CV disease, and multiple inhibitors of the pathway have been shown to improve outcomes in chronic HF. 1, 4, 7, 19 However, the inhibition of downstream pathway activity can produce a compensatory rise in plasma renin activity that can competitively overcome RAAS blockade. Aliskiren is a DRI with a favorable neurohormonal and hemodynamic profile that offers the theoretical advantage of RAAS blockade at the most proximal step, thus minimizing the effects of RAAS escape. [8] [9] [10] Given the neurohormonal and hemodynamic perturbations present during and after HF hospitalization, 20, 21 it was hypothesized that adding aliskiren to standard therapy would lead to reductions in postdischarge mortality and rehospitalization. The main results of the ASTRONAUT trial do not validate the original hypothesis. The only secondary end point achieved in ASTRONAUT was the change from baseline in NT-proBNP level. Despite a significant and sustained reduction in natriuretic peptide level, a known marker of HF severity, aliskiren did not reduce mortality or rehospitalization rates. 22 It is possible that a beneficial effect on HF progression, as suggested by this long-term improvement in natriuretic peptide level, was offset by potential negative drug-associated effects, perhaps particularly in patients with DM.
The subgroup analysis of the 6-month primary end point did not show heterogeneity for any of the subgroups tested. However, subgroup analyses for 12-month end points of CV death or HF rehospitalization and allcause death revealed a statistically significant interaction by history of DM. The bidirectional effect of aliskiren on 12-month all-cause death for patients with and without DM is notable given the results of the recent ALTITUDE study in which poor outcomes with aliskiren for patients with DM and concerns regarding renal dysfunction, hyperkalemia, hypotension, and stroke resulted in premature study termination. 18 While ASTRONAUT did not strictly enroll patients with DM, it failed to reproduce the same pattern of clinical outcomes observed in ALTITUDE, which may suggest the role of chance. The results of ALTITUDE indicated that all components of the primary outcome (including CV death, myocardial infarction, stroke, end-stage renal disease/renal death), with the exception of unplanned hospitalization for HF, were nominally more frequent in the aliskiren group. Moreover, a statistically significant greater number of patients receiving aliskiren experienced cardiac arrest with resuscitation. In contrast, in ASTRONAUT, nominally fewer aliskiren-treated patients experienced CV death, stroke, myocardial infarction, and resuscitated sudden death compared with placebo-treated patients, with myocardial infarction reaching statistical significance. The precise reasons underlying the poor outcomes among patients with DM receiving aliskiren are unknown and likely complex but may be related to increased risk of hypotension, hyperkalemia, and worsening renal function with the study drug. The exact mechanisms accounting for adverse outcomes in patients with DM and potentially improved outcomes in patients without DM deserve further analysis. However, irrespective of mechanism, the influence of baseline DM on event rate further highlights the heterogeneity of clinical profiles seen in HHF and suggests a role for further patient stratification in future studies. 23, 24 The ongoing long-term Aliskiren Trial of Minimizing Outcomes in Patients with Heart Failure (ATMOSPHERE), which will include data for patients with DM, may provide further insights. 25 Although the diabetes subgroup findings are intriguing, they must be interpreted with caution because of the wellknown statistical limitations (ie, low number of patients by subgroup, multiplicity adjustment). 26 This may be particularly relevant in the specific case of ASTRONAUT, in which the observed findings were not based on the primary end point (where there was no significant subgroupϫtreatment interaction) but rather on select secondary end points. Hence, the role of chance cannot be excluded.
To our knowledge, ASTRONAUT is the first multicenter, international study that randomized stable, but hospitalized, patients with chronic HF several days after admission (median 5 days). This added time between hospital admission and randomization allowed for clinical and hemodynamic stabilization, as reflected in improvements in NYHA functional class and natriuretic peptide levels. Despite this stabilization and the use of evidence-based therapies, risk of death and rehospitalization remained high.
Prior prospective HF studies have focused primarily on (1) worsening chronic HF requiring hospitalization and short-term acute interventions to treat significant signs, symptoms, and hemodynamic derangements or (2) chronic stable ambulatory patients. ASTRONAUT may serve as the model for future trials in stabilized HHF patients. Given that HF is a chronic condition, a 1-to 2-day in-hospital therapy is unlikely to change the natural history of disease. Rather, a study design similar to ASTRONAUT with inhospital initiation of therapy for stable patients and subsequent outpatient continuation may offer the best chance of improving outcomes. Moreover, given the persistently high postdischarge event rate confirmed in ASTRONAUT, future HF trials are encouraged to prioritize study of this population over outpatients with chronic HF who have a lower event rate.
27
CONCLUSIONS
In HHF patients with reduced LVEF, the addition of aliskiren to standard therapy had no significant effect on the primary combined end point of CV mortality or HF rehospitalization at 6 months. The results of the ASTRONAUT study do not support t h e r o u t i n e a d m i n i s t r a t i o n o f aliskiren, in addition to standard therapy, to patients hospitalized for worsening chronic HF. Subgroup analysis is consistent with previous reports of poor outcomes with the use of aliskiren in patients with DM already taking RAAS inhibitors. Further investigations are needed to evaluate the effects of renin inhibition in a large cohort of HHF patients that excludes patients with DM.
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